P/B
6,9
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
$111.5M
Market Cap • 9/11/2026
2001
(25 years)
Founded
2023
(3 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
13941,2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,4
EPS
—
Market Cap
Market Cap
111,5M
EV
95,3M
EV/Revenue
11910
EV/EBITDA
-2,6
EV/EBIT
-2,6
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,1%
Total Yield
-0,1%
Payout
0%
Retained Earnings
-301,9M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
283513%
Capex/Revenue
42575%
Capex/D&A
2398,6%
Capex/OCF
-13,5%
SBC/OCF
—
% PPE
26,4%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
0,4
Debt/Equity
0%
Current Ratio
2,4
Quick Ratio
2,3
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!